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Abstract
Prostate cancer (PCa) is one of the most common malignancies associated with bone 
metastases, and palliative radiation therapy (RT) is an effective treatment option. A 
total of 2641 patients were identified with PCa and bone metastases at diagnosis 
from 2010 to 2014 in the NCDB. Fractionation scheme was designated as short 
course ([SC- RT]: 8 Gy in 1 fraction and 20 Gy in 5 fractions) vs long course ([LC- 
RT]: 30 Gy in 10 fractions and 37.5 Gy in 15 fractions). Patient characteristics were 
correlated with fractionation scheme using logistic regression. Overall survival was 
analyzed using the Kaplan- Meier method, log- rank test, Cox proportional hazards 
models, and propensity score- matched analyses. A total of 2255 (85.4%) patients 
were included in the LC- RT group and 386 (14.6%) patients in the SC- RT group. 
SC- RT was more common in patients over 75 years age (odds ratio [OR]: 1.70, 95% 
confidence interval [CI] 1.32- 2.20), treatment at an academic center (OR: 1.76, 1.20- 
2.57), living greater than 15 miles distance to treatment facility (OR: 1.38, 1.05- 
1.83), treatment to the rib (OR: 2.99, 1.36- 6.60), and in 2014 (OR: 1.73, 1.19- 2.51). 
RT to the spine was more commonly long course (P < .0001). In the propensity- 
matched cohort, LC- RT was associated with improved OS (P < .0001), but no OS 
difference was observed between 37.5 Gy and either 8 Gy in one fraction or 20 Gy in 
5 fractions (P > .5). LC-RT remains the most common treatment fractionation 
scheme for palliative bone metastases in PCa patients. Use of palliative SC- RT is 
increasing, particularly in more recent years, for older patients, treatment at aca-
demic centers, and with increasing distance from a treatment center.
K E Y W O R D S
metastatic prostate cancer, National Cancer Database, palliative radiation
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1 |  INTRODUCTION
Prostate cancer is among the most frequently diagnosed ma-
lignancies in men and is one of the most common malignan-
cies associated with osseous metastases.1-3 Since 2007, the 
incidence of metastatic prostate cancer at diagnosis has risen 
significantly.4 Patients who present with bone metastases at 
diagnosis often have significant pain or other skeletal- related 
comorbidities. Radiation therapy (RT) is a safe and highly 
effective means to alleviate symptoms from bone metasta-
ses. Many different dose fractionation schedules have been 
reported, with 30 Gy in 10 fractions the most common sched-
ule in the United States.2 Multiple prospective randomized 
trials and meta- analysis have analyzed pain- related outcomes 
with multifraction radiation therapy compared to single or 
shorter fraction treatments and have found similar pain con-
trol.5-9 Given these findings, and the potential to decrease 
the financial burden on the healthcare system, many medi-
cal societies including the American Society for Radiation 
Oncology (ASTRO) have released practice guidelines advo-
cating single fraction or shorter course radiotherapy.10 In this 
study, we analyzed prostate cancer patients with metastatic 
bone disease present at diagnosis from the National Cancer 
Database (NCDB) to investigate patterns of care and overall 
survival. Of particular interest were changes in the patterns 
of care following ASTRO’s bone metastasis evidence- based 
guidelines and recommendations.10,11
2 |  MATERIALS AND METHODS
2.1 | Data source and study population
The NCDB Participant User File (PUF) for prostate tu-
mors was reviewed to identify all patients between 18 and 
90 years of age with a diagnosis of prostate cancer with 
bone metastases present at diagnosis. The NCDB is a joint 
program of the American College of Surgeons and the 
American Cancer Society. Data from approximately 70% 
of patients diagnosed at Commission on Cancer- accredited 
cancer centers are included with patient, tumor, and treat-
ment characteristics. Data elements are collected and sub-
mitted to the NCDB from commission- accredited oncology 
registries using standardized coding and data item defini-
tions, including RT dose/technique, chemotherapy use/tim-
ing, and Charlson- Deyo comorbidity score. The Participant 
User File contains de- identified patient and center infor-
mation and was exempt from Institutional Review Board 
review.
De- identified data for patients diagnosed with prostate 
cancer (PUF code: Primary Site = C619) who were diag-
nosed between 2010 and 2014 were evaluated. All included 
patients had bone metastases at the time of diagnosis (PUF 
code: CS Mets at DX- Bone = 1) and were coded in the 
database as analytical Stage 4 (M1b). Demographic and clini-
cal data included age, race, year of diagnosis, Charlson- Deyo 
comorbidity index (CCI), treatment location and facility type, 
income, distance to treatment facility, primary insurance sta-
tus, tumor T- stage, and when available Gleason Score and 
PSA. Radiation treatment schedules were classified as short 
course (SC- RT: 8 Gy in 1 fraction and 20 Gy in 5 fractions) 
or long course (LC- RT: 30 Gy in 10 fractions and 37.5 Gy in 
15 fractions). Only patients receiving RT to the bone were 
included (spine, ribs, hip, pelvic bones, shoulder, and ex-
tremity). We excluded patients who received radiation to the 
“Spinal Cord” who may have had spinal cord compression. 
Data regarding overall survival (OS) were available from pa-
tients with diagnosis between 2010 and 2013.
2.2 | Statistical analysis
Descriptive statistics were used to analyze patterns of frac-
tionation scheme use. The chi- square test and Fisher’s exact 
test were used to evaluate contingency tables, as appropri-
ate. Logistic regression was used to assess for predictors of 
SC- RT compared to LC- RT. Variables with P- values <.1 on 
univariate testing were entered into a multivariable analy-
sis. Propensity score analysis was performed to correct for 
baseline differences between short- course and long- course 
groups. A matching algorithm including the variables used in 
univariate analysis, as well as receipt of hormone therapy and 
chemotherapy, was used with a caliper of 0.2. Exact match-
ing was performed on the “treatment site” variable. Overall 
survival was calculated from diagnosis until death, censoring 
at last follow- up for patients who were alive. The Kaplan- 
Meier method was used to estimate overall survival probabil-
ities and multivariable Cox regression was performed on all 
patients using the same variables as above. Significance was 
considered at a value of P < .05. All levels of significance 
were two- sided. SPSS Statistics v.24 (IBM Corporation; 
Armonk, New York) was used for all statistical analyses.
3 |  RESULTS
3.1 | Demographics and patient 
characteristics
A total of 2641 patients were included in the analysis. A 
total of 2255 (85.4%) patients were included in the LC- RT 
group, and 386 (14.6%) patients were included in the SC- 
RT group. One hundred and forty- three (5.4%) received 
8 Gy in 1 fraction, 243 (9.2%) patients received 20 Gy in 
5 fractions, 1915 (72.5%) patients received 30 Gy in 10 
fractions, and 340 (12.9%) patients received 37.5 Gy in 
15 fractions. Median age of patients in the SC- RT group 
was 73 years (range, 42- 90) vs 69 years (range, 39- 90) 
for the LC- RT group. The frequency of SC- RT increased 
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from 11.3% in 2010 to 18.8% in 2014 (Figure 1). The most 
common site of bone metastases was spine (65.2%), hip 
(13.7%), pelvis (10.0%), and extremity (7.7%). 13.1% of 
patients living within 5 miles of their treatment facility re-
ceived SC- RT compared to 17.2% of patients living greater 
than 15 miles (P = .019). Complete details of patient char-
acteristics are available in Table 1.
3.2 | Univariable and multivariable 
logistic regression
On multivariable analysis, variables associated with increased 
likelihood of receiving SC- RT included the following: in-
creasing year of age (OR: 1.03, 95% confidence interval [CI] 
1.01- 1.04; P < .0001), age group >70 years (OR: 1.56, (95% 
CI 1.25- 1.94); P < .0001), age group >75 years (OR: 1.70, 
(95% CI 1.32- 2.20); P < .0001), most recent year (2014) of 
diagnosis (OR: 1.73, (95% CI 1.19- 2.51); P = .004), year 
of diagnosis (2013- 2014) (OR: 1.50, (95% CI 1.11- 2.12); 
P = .01), treatment at an academic/research program (OR: 
1.76, (95% CI 1.20- 2.57); P = .004), treatment to the rib 
(OR: 2.99, (95% CI 1.36- 6.60); P = .007), and living >15 
miles from treatment facility (OR: 1.38, (95% CI 1.05- 1.83); 
P = .023). Regarding distance from treatment facility, with 
each increase in mile from the treatment center, there was an 
increased likelihood of receiving SC- RT (OR: 1.01, (95% CI 
1.00- 1.02); P = .040). Treatment to the spine was more com-
monly treated with LC- RT (OR: 0.49, (95% CI 0.34- 0.71); 
P < .0001). CCI, insurance status, and income were not asso-
ciated with receipt of either fractionation scheme. Complete 
details of both univariable and multivariable analysis are 
found in Table 2.
3.3 | Outcomes
The median follow- up was 19.2 months. The median OS of 
the entire cohort was 24.3 months (95% confidence interval 
[CI], 22.7- 25.8 months). Patients treated with SC- RT had 
median OS of 14.9 months (95% CI, 12.7- 17.2) compared 
to 25.9 (95% CI, 24.1- 27.7) months for LC- RT (P < .0001) 
(Figure 2). The median overall survival for patients treated 
with 8 Gy in a single fraction was 15.2 months (95% CI, 
11.1- 19.3) vs 14.8 months (95% CI, 12.0- 17.6) for those 
treated with 20 Gy in 5 fractions (P = .832). There was also 
no significant difference in OS between those treated with 
30 Gy in 10 fractions and 37.5 Gy in 15 fractions (P = .758).
3.4 | Univariate and multivariable 
Cox analyses
On univariate analyses, OS was affected by length of radia-
tion course (SC vs LC), receipt of hormone therapy, age, CCI, 
insurance status, distance to treatment facility, and clinical T- 
stage (Table 3). On multivariable analysis, factors associated 
with worse OS included the following: short course of RT 
course (HR: 1.57 [95% CI, 1.34- 1.85]; P < .0001), no hor-
mone therapy (HR: 1.36 [95% CI, 1.13- 1.63]; P = .001), age 
>75 years (HR: 1.70 [95% CI, 1.32- 2.20]; P < .0001), and 
CCI ≥ 1 (for >1, HR: 1.44 [95% CI, 1.17- 1.78]; P = .001).
3.5 | Matched Cohort
Propensity score matching between the SC- RT and LC- RT 
groups was performed to address confounding patient, tumor, 
and demographic bias between the groups. A propensity score 
match resulted in successful match of 242 pairs of patients 
between SC and LC- RT (484 total patients). There were no 
significant imbalances in matched variables in the resulting 
cohort, and propensity scores were well matched (all standard-
ized mean differences < 0.2). In the matched cohort, median 
OS for LC- RT patients was 24.7 months (95% CI, 19.2- 30.3) 
vs. 14.8 months (95% CI, 12.4- 17.1) for patients treated with 
SC- RT (P < .0001, Figure 3A). In analysis of the individual 
RT groups, there was no statistically significant difference in 
OS between 37.5 Gy in 15 fractions, 20 Gy in 5 fractions, and 
8 Gy in 1 fraction (8 Gy vs 20 Gy, P = .776; 8 Gy vs 37.5 Gy, 
P = .409; 20 Gy vs 37.5 Gy, P = .278) (Figure 3B). The long-
est median OS was seen in those patients receiving 30 Gy in 
10 fractions (30 Gy vs 8 Gy and 20 Gy, P < .0001; 30 Gy vs 
37.5 Gy, P = .513). On multivariable analysis factors associ-
ated with worse OS included the following: short course of 
RT course (HR: 1.45 [95% CI, 1.22- 1.67]; P < .0001), no 
hormone therapy (HR: 1.38 [95% CI, 1.15- 1.69]; P = .001), 
age >75 years (HR: 1.75 [95% CI, 1.42- 2.29]; P < .0001), and 
CCI ≥ 1 (for >1, HR: 1.54 [95% CI, 1.31- 1.88]; P < .0001).
4 |  DISCUSSION
Prostate cancer is among the most common malignancies 
to metastasize to bone, and of those patients dying from 
F I G U R E  1  Distribution of short- course radiation therapy (SC- 
RT) by year of diagnosis (N = 2641 patients; 386 received SC- RT)
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T A B L E  1  Demographics and clinical characteristics
Percentage of patients (#)
Short course Long course P- value
Age
<75 y 12.2% (207) 87.8% (1486) <.0001
≥75 y 18.9% (179) 81.1% (769)
Race
White 14.1% (292) 85.9% (1774) .246
Black 15.6% (70) 84.4% (380)
Other 19.2% (24) 80.8% (101)
Year of diagnosis
2010 11.3% (44) 88.7% (345) .003
2011 12.2% (55) 87.8% (396)
2012 13.8% (70) 86.2% (439)
2013 14.4% (85) 85.6% (506)
2014 18.8% (132) 81.2% (569)
Charlson- Deyo comorbidity
0 14.0% (284) 86.0% (1741) .296
1 16.5% (70) 83.5% (354)
>1 16.7% (32) 83.3% (160)
Site of treatment
Spine 11.8% (204) 88.2% (1518) <.0001
Ribs 46.9% (15) 53.1% (17)
Hip 17.4% (63) 82.6% (300)
Pelvic bones 17.4% (46) 82.6% (219)
Shoulder 21.8% (12) 78.2% (43)
Extremity 22.5% (46) 77.5% (158)
Facility type
Academic/Research Program 19.7% (181) 80.3% (736) <.0001
Community Caner Program 12.9% (37) 87.1% (250)
Comprehensive Community Cancer Program 11.4% (128) 88.6% (994)
Integrated Network Cancer Program 12.7% (40) 87.3% (275)
Insurance status
Medicaid 17.0% (38) 83.0% (186) .021
Medicare 15.9% (234) 84.1% (1239)
Not insured 12.0% (22) 88.0% (162)
Other government 23.9% (11) 76.1% (35)
Private 11.3% (76) 88.7% (594)
Unknown 11.4% (5) 88.6% (39)
Income
<$38 000 14.4% (73) 85.6% (435) .907
$38 000- 47 999 13.5% (84) 86.5% (536)
$48 000- 62 999 15.3% (110) 84.7% (611)
>$63 000 15.1% (117) 84.9% (659)
Unknown 12.5% (2) 87.5% (14)
(Continues)
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prostate cancer, the rate of skeletal involvement ranges 
between 85 and 100% within 10 years of a metastatic di-
agnosis despite hormone therapy.12-15 Bone metastases 
from prostate cancer are commonly associated with sig-
nificant morbidity including pathological fracture, spinal 
cord compression, pain, and other skeletal- related events. 
The current standard of care for palliation of pain and pre-
vention of further morbidity caused by bone metastases is 
external beam radiation therapy. Multiple radiation frac-
tionation schemes are used in the palliative setting with 
longer course (ie, >10 fractions) being more common in 
the United States.2 This is despite equivalent pain control 
and response rates with single fraction or shorter course 
treatments in several prior randomized studies and a large 
meta- analysis.5-7,16-18 Similar to prior reports, in this large 
hospital- based study of patients with bone metastases at 
diagnosis, we found that ≥10 treatments remain the domi-
nant fractionation scheme in the United States from 2010 
to 2014 (85.4%).
Numerous clinical and demographic factors influence 
decisions pertaining to the choice of fractionation scheme 
in the treatment of bone metastases. These factors include, 
but are not limited to, many of the variables investigated in 
this study. We observed that those patients most likely to 
SC- RT were those that were older, treated at an academic/
research facility, received radiation o the rib, and lived 
over 15 miles from the treatment center. Additionally, we 
found that patients diagnosed in the most recent year eval-
uated (2014) were more likely to receive SC- RT on logistic 
regression.
Multiple previous studies have observed that older pa-
tients are more likely to receive short- course palliative radi-
ation therapy.2,19 This is likely due to the increasing medical 
comorbidities and declining performance status associated 
with increased age. While we incorporated Charlson- Deyo 
comorbidity in our analysis, we did not appreciate an as-
sociation between comorbidity score and selection of frac-
tionation scheme. This is likely due to inherent difficulties 
capturing true comorbidity in the NCDB and lack of docu-
mented performance status. It can also be hypothesized that 
elderly patients likely have more difficulty in transportation 
to treatment facilities and are therefore more likely to receive 
SC- RT. Our analysis found that patients residing more than 
15 miles from a treatment facility were more likely to receive 
SC- RT which supports this hypothesis. The trend toward 
more frequent use of SC- RT also increased as the distance to 
treatment center was increased as well.
Our study also found that patients treated at academic/
research facilities were more likely to receive SC- RT than 
at nonacademic facilities. This finding is in keeping with 
studies in other disease sites, particularly breast cancer, 
that have reported earlier adoption of short- course radia-
tion therapy at academic centers compared to community 
practice as randomized trial evidence has emerged sup-
porting the move to shorter radiation courses.15,20 There 
are multiple potential explanations for this observation. 
Physician training and a lack of comfort with short- course 
palliative radiation therapy, particularly single fraction 
treatment, clearly plays an important role in limiting the 
adoption of short- course palliative treatments. These fac-
tors may be somewhat mitigated at academic centers in 
which the development and adoption of new treatment 
strategies are emphasized. It is unclear to what extent dif-
ferences in reimbursement between short- course and lon-
ger course palliative radiation influence behavior, but the 
current reimbursement model introduces bias in favor of 
longer courses of radiation. Differential reimbursement 
has been documented to influence choices among pallia-
tive treatments, such as palliative chemotherapy regimens, 
and this relationship is likely also present in radiation ther-
apy decision making.19-21 Interestingly, our findings did 
not show any association between treatment scheme and 
patient insurance status, with uninsured patients no more 
likely to receive SC- RT.
Anatomic location of bone metastases was also associated 
with the receipt of SC- RT. Patients with rib metastases were 
more likely to receive a SC regimen and those with spine 
metastases more likely to receive a longer course. While we 
attempted to exclude patients with documented spine cord 
compression, this finding likely represents the use of LC- RT 
Percentage of patients (#)
Short course Long course P- value
Distance
0- 5 miles 13.1% (117) 86.9% (775) .019
>5- 10 miles 12.3% (79) 87.7% (561)
>10- 15 miles 16.9% (56) 83.1% (276)
>15 miles 17.2% (134) 82.8% (643)
Bold values represent statistical significance between short-course and long-course radiation therapy (P < 0.05).
T A B L E  1  (Continued)
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T A B L E  2  Univariate and multivariate logistic regression for short- course RT
Univariate Multivariate
Odds ratio P- value Odds ratio P- value
Age
<70 y Reference Group Reference Group
≥70 y 1.56 (1.25-1.94) <.0001 1.58 (1.30-2.18) <.0001
<75 y Reference Group Reference Group
≥75 y 1.67 (1.34-2.08) <.0001 1.70 (1.32-2.20) <.0001
Race
White Reference Group —
Black 1.12 (0.84- 1.50) .436
Other 1.44 (0.91- 2.29) .119
Year of diagnosis
2010 Reference Group Reference Group
2011 1.09 (0.71- 1.66) .692 1.06 (0.69- 1.64) .786
2012 1.25 (0.84- 1.87) .277 1.22 (0.81- 1.83) .353
2013 1.32 (0.89- 1.94) .165 1.30 (0.86- 1.94) .192
2014 1.82 (1.26-2.62) .001 1.73 (1.19-2.51) .004
Charlson- Deyo Comorbidity
0 Reference Group —
1 1.21 (0.91- 1.61) .186
>1 1.23 (0.82- 1.83) .318
Site of treatment
Extremity Reference Group Reference Group
Spine 0.46 (0.32-0.66) <.0001 0.49 (0.34-0.71) <.0001
Ribs 3.03 (1.41-6.53) .005 2.99 (1.36-6.60) .007
Hip 0.72 (0.47- 1.11) .133 0.79 (0.51- 1.22) .290
Pelvic bones 0.72 (0.46- 1.14) .161 0.77 (0.49- 1.24) .289




Reference Group Reference Group
Academic/Research 
Program
1.69 (1.17-2.45) .005 1.76 (1.20-2.57) .004
Community Caner 
Program




0.89 (0.61- 1.29) .529 0.88 (0.59- 1.29) .505
Insurance status
Not insured Reference Group Reference Group
Medicaid 1.54 (0.85- 2.65) .157 1.45 (0.81- 2.61) .207
Medicare 1.39 (0.87- 2.22) .166 1.08 (0.66- 1.78) .757
Other government 2.31 (1.03-5.21) .043 1.78 (0.77- 4.12) .180
Private 0.94 (0.57- 1.56) .817 0.89 (0.53- 1.49) .652
Unknown 0.94 (0.34- 2.65) .913 0.95 (0.33- 2.72) .926
(Continues)
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for more durable control in the setting of spine metastases to 
prevent cord compression. This is supported by studies that 
have shown that the 18%- 20% retreatment rate in single frac-
tion radiotherapy which is approximately double that of 10 
or more fractions.2 It has been reported, however, that 16 Gy 
in 2 fractions or 8 Gy in one fraction are also effective in the 
treatment of metastatic cord compression.22
Another finding from this study is the increasing use of 
SC- RT in the most recent time period examined. Schreiber 
et al2 published a similar study using the NCDB with met-
astatic prostate patients diagnosed between 2004 and 2012. 
In their study, longer fractionations schemes (≥10) were 
used in over 91% of patients. They did find, however, that 
year of diagnosis 2009 or later was associated with an in-
creased likelihood of receiving SC- RT. It may be considered 
that further increased use observed in our study coincides 
with multiple medical associations recommending shorter 
treatment courses. In 2011, Lutz et al10 published “Palliative 
Radiotherapy for Bone Metastasis: An ASTRO Evidence- 
Based Guideline”. Following publication, it was noted to 
be one of the most downloaded International Journal of 
Radiation Oncology, Biology, and Physics articles each year 
for 4 years following publication.23 It was our hypothesis that 
following the release of these guidelines, a slow but apparent 
increase in SC- RT would be appreciated. In our analysis, the 
frequency of SC- RT increased from 11.3% in 2010 to 18.8% 
in 2014. In subgroup analysis, the rate of single fraction pal-
liative radiation therapy also increased over the same time 
period (3.8% over 4 years).
However, there is ambiguity in the recommendations 
provided by ASTRO.24 The guidelines suggest that there is 
equivalent pain relief following 30 Gy in 10 fractions, 20 Gy 
in 5 fractions, or a single 8 Gy fraction, but do not frankly 
recommend adoption of short- course or single fraction RT 
despite randomized evidence showing equivalence of the dif-
ferent fractionation schemes. For example, both the Choosing 
Wisely Canada campaign and The American Academy of 
Hospice and Palliative Medicine Choosing Wisely campaign 
are direct stating: “Don’t recommend more than a single 
fraction of palliative radiation for an uncomplicated painful 
bone metastasis.”25,26 Perhaps with a more firm stance from 
ASTRO adoption of shorter course RT would be imple-
mented in the United States, similar to the more prevalent use 
seen in other countries such as Canada and the UK.19
In this study, we found that overall survival was superior 
in the group of patients treated with LC- RT on multivariable 
analysis. This overall survival finding is consistent with prior 
database reports, and is likely due to factors influencing the 
selection of radiation therapy treatment scheme that cannot 
Univariate Multivariate
Odds ratio P- value Odds ratio P- value
Income
<$38 000 Reference Group —
$38 000- 47 999 0.93 (0.67- 1.31) .692
$48 000- 62 999 1.07 (0.78- 1.48) .667
>$63 000 1.06 (0.77- 1.45) .727
Unknown 0.85 (0.19- 3.82) .834
Distance
0- 5 miles Reference Group Reference Group
>5- 10 miles 0.93 (0.69- 1.27) .655 0.91 (0.66- 1.25) .557
>10- 15 miles 1.34 (0.95- 1.90) .095 1.31 (0.91- 1.87) .143
>15 miles 1.38 (1.05-1.81) .019 1.38 (1.05-1.83) .023
Bold value represent statistical significance of the odds ratio between short-course and long-course radiation therapy (P < 0.05).
T A B L E  2  (Continued)
F I G U R E  2  Kaplan- Meier overall survival curve of patients 
treated with long- course radiation therapy (LG- RT) vs short- course 
radiation therapy (SC- RT). P < .0001
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T A B L E  3  Univariate and multivariate Cox regression for overall survival
Univariate Multivariate
Hazard ratio P- value Hazard ratio P- value
Fractionation scheme
Long- Course RT Reference Group Reference Group
Short- Course RT 1.64 (1.40-1.92) <.0001 1.57 (1.34-1.85) <.0001
Hormone therapy
Yes Reference Group Reference Group
No 1.42 (1.19-1.71) <.0001 1.36 (1.13-1.63) .001
Chemotherapy
Yes Reference Group —
No 0.94 (0.75- 1.18) .617
Clinical T- Stage
T1 Reference Group Reference Group
T2 1.04 (0.86- 1.25) .676 1.00 (0.83- 1.20) .970
T3 0.83 (0.51- 1.36) .436 0.94 (0.73- 1.20) .598
T4 1.32 (1.05-1.66) .018 1.26 (1.00- 1.58) .054
TX 1.11 (0.78- 1.59) .556 1.01 (0.70- 1.46) .949
Unknown 1.24 (1.06-1.45) .008 1.17 (0.99- 1.37) .061
Age
<75 y Reference Group Reference Group
≥75 y 1.52 (1.41-1.78) <.0001 1.70 (1.32-2.20) <.0001
Race
White Reference Group —
Black 0.92 (0.79- 1.07) .292
Other 0.78 (0.58- 1.05) .099
Year of diagnosis
2010 Reference Group —
2011 0.90 (0.76- 1.05) .177
2012 1.0 (0.85- 1.17) .969
2013 0.93 (0.78- 1.10) .400
Charlson- Deyo Comorbidity
0 Reference Group Reference Group
1 1.19 (1.02-1.39) .030 1.19 (1.02-1.38) .029
>1 1.59 (1.29-1.95) <.0001 1.44 (1.17-1.78) .001
Site of treatment
Extremity Reference Group —
Spine 1.10 (0.88- 1.38) .388
Ribs 1.43 (0.83- 2.47) .204
Hip 0.88 (0.67- 1.15) .340
Pelvic bones 0.92 (0.70- 1.22) .577
Shoulder 1.29 (0.87- 1.92) .210
Facility type
Integrated Network Cancer 
Program
Reference Group —
Academic/Research Program 0.86 (0.70- 1.04) .124
(Continues)
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be measured in the NCDB. In a propensity- matched cohort, 
we continued to find an improved overall survival benefit to 
LC- RT; however, in subgroup analysis, there was no overall 
survival benefit to 37.5 Gy in 15 fractions compared to either 
short- course fractionation scheme evaluated. This conflicts 
the idea that more aggressive local palliative radiation ther-
apy is associated with improved overall survival, and sup-
ports that patients selected for 30 Gy in 10 fractions likely 
have selection bias that cannot be measured in the NCDB.
Lastly, the adoption of single fraction or short- course RT 
has significant financial implications for the radiation and 
medical community. A Dutch randomized controlled trial of 
1157 patients with painful bone metastases compared both 
pain responses and cost of radiotherapy. They found no dif-
ference in pain response, and that the estimated cost of radi-
ation therapy, including retreatments and other nonmedical 
costs, was significantly lower for a single fraction schedule 
compared to multiple fraction schedule ($2438 vs $3311, 
difference = $873, 95% confidence interval on the differ-
ence = $449 to $1297; P < .001).27 The Radiation Oncology 
Group (RTOG) found a similar financial advantage with sin-
gle fraction over longer treatment courses in evaluation of 
RTOG 9714.28 In a New Zealand study, patient costs for sin-
gle fraction RT were NZ$1344 (95% uncertainty level $855 
to $1846) lower than multifraction RT for palliative bone 
metastases in the prostate cancer setting.29 Additionally, a 
recent SEER analysis reported a difference of $3094 (95% 
CI: $2107- 4081) between single fraction and 10 or longer 
fractionation schemes.30 There are estimates that an absolute 
increase of 10% use of single fraction palliative radiation 
therapy for metastatic prostate cancer could generate over 
$70 million per year in health cost savings.2,31,32
There are several limitations to this study, many of which 
are inherent to the NCDB and a retrospective analysis. The 
lack of clinical details regarding the specifics of each bone 
metastases is a major limitation. For example, degree of 
pain, number of metastases, complicated vs uncomplicated 
lesions, and additional courses of radiotherapy are all lack-
ing from the database and likely significantly contribute to 
the selection of fractionation scheme. Additionally, while 
the NCDB codes for Charlson- Deyo comorbidity, there are 
significant limitations to this variable in the NCDB and 
true comorbidities are likely vastly underestimated. The in-
formation regarding time to palliative RT is poorly coded 
in the database, and it may be possible that the length of 
life from time of metastatic diagnosis and need for pallia-
tive treatment may impact fractionation scheme of RT and 
survival. Lastly, there are no data in the NCDB regarding 
Univariate Multivariate
Hazard ratio P- value Hazard ratio P- value
Community Caner Program 1.10 (0.87- 1.41) .423
Comprehensive Community 
Cancer Program
0.86 (0.70- 1.04) .498
Insurance status
Not insured Reference Group Reference Group
Medicaid 1.06 (0.78- 1.43) .705 1.04 (0.77- 1.41) .795
Medicare 1.32 (1.05-1.67) .018 1.09 (0.85- 1.34) .499
Other government 1.06 (0.63- 1.78) .836 1.02 (0.60- 1.72) .946
Private 0.87 (0.68- 1.12) .281 0.86 (0.67- 1.11) .246
Unknown 0.98 (0.60- 1.62) .939 0.88 (0.53- 1.46) .167
Income
<$38 000 Reference Group —
$38 000- 47 999 0.97 (0.82- 1.15) .722
$48 000- 62 999 0.94 (0.79- 1.11) .445
>$63 000 0.92 (0.78- 1.08) .303
Unknown 1.92 (0.99- 3.75) .054
Distance
0- 5 miles Reference Group Reference Group
>5- 10 miles 0.87 (0.75- 1.01) .074 0.85 (0.73-0.99) .042
>10- 15 miles 0.75 (0.62-0.91) .003 0.73 (0.60-0.90) .002
>15 miles 0.92 (0.80- 1.06) .251 0.92 (0.79- 1.06) .230
Bold value represent statistical significance of the hazards ratio between short-course and long-course radiation therapy (P < 0.05).
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effectiveness or toxicity of RT, and overall survival is the 
only survival outcome available.
5 |  CONCLUSION
In this large observational study of the NCDB, the most com-
mon palliative radiation fraction scheme for men with pros-
tate cancer and metastatic bone disease at diagnosis is ≥10 
fractions. Despite recommendations from numerous medical 
societies and randomized data showing equivalent pain con-
trol with shorter treatment courses, LC- RT remains the dom-
inant fractionation scheme in the United States. Increasing 
age, treatment at an academic/research center, treatment to 
the rib, increasing distance to treatment facility, and diag-
nosis in 2014 were associated with increased likelihood of 
receiving short- course RT. Increasing use of shorter fraction-
ation schemes would provide significant costs reductions in 
healthcare spending.
CONFLICT OF INTEREST
Authors have no conflict of interests.
ORCID
Benjamin W. Fischer-Valuck  http://orcid.org/0000-0003-2348-9710 
REFERENCES
 1. Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survi-
vorship statistics, 2016. CA Cancer J Clin. 2016;66:271‐289.
 2. Schreiber D, Safdieh J, Becker DJ, Schwartz D. Patterns of care 
and survival outcomes of palliative radiation for prostate cancer 
with bone metastases: comparison of </=5 fractions to >/=10 
fractions. Ann Palliat Med. 2017;6:55‐65.
 3. Tofe AJ, Francis MD, Harvey WJ. Correlation of neoplasms 
with incidence and localization of skeletal metastases: an 
analysis of 1,355 diphosphonate bone scans. J Nucl Med. 
1975;16:986‐989.
 4. Weiner AB, Matulewicz RS, Eggener SE, Schaeffer EM. Increasing 
incidence of metastatic prostate cancer in the United States (2004- 
2013). Prostate Cancer Prostatic Dis. 2016;19:395‐397.
 5. Yarnold JR. 8 Gy single fraction radiotherapy for the treatment 
of metastatic skeletal pain: randomised comparison with a multi-
fraction schedule over 12 months of patient follow- up. Bone Pain 
Trial Working Party. Radiother Oncol. 1999;52:111‐121.
 6. Kaasa S, Brenne E, Lund JA, et al. Prospective randomised mul-
ticenter trial on single fraction radiotherapy (8  Gy x 1) versus 
multiple fractions (3 Gy x 10) in the treatment of painful bone 
metastases. Radiother Oncol. 2006;79:278‐284.
 7. Hartsell WF, Scott CB, Bruner DW, et  al. Randomized trial of 
short- versus long- course radiotherapy for palliation of painful 
bone metastases. J Natl Cancer Inst. 2005;97:798‐804.
 8. Steenland E, Leer JW, van Houwelingen H, et al. The effect of 
a single fraction compared to multiple fractions on painful bone 
metastases: a global analysis of the Dutch Bone Metastasis Study. 
Radiother Oncol. 1999;52:101‐109.
 9. Ben-Josef E, Shamsa F, Youssef E, Porter AT. External beam ra-
diotherapy for painful osseous metastases: pooled data dose re-
sponse analysis. Int J Radiat Oncol Biol Phys. 1999;45:715‐719.
 10. Lutz S, Berk L, Chang E, et al. Palliative radiotherapy for bone 
metastases: an ASTRO evidence- based guideline. Int J Radiat 
Oncol Biol Phys. 2011;79:965‐976.
 11. Hahn C, Kavanagh B, Bhatnagar A, et al. Choosing wisely: the 
American Society for Radiation Oncology’s top 5 list. Pract 
Radiat Oncol. 2014;4:349‐355.
F I G U R E  3  Propensity- matched cohort. A, Kaplan- Meier overall 
survival curve of patients treated with long- course radiation therapy 
(LG- RT) vs short- course radiation therapy (SC- RT). P < .0001. B, 
Kaplan- Meier overall survival curve of patients treated with 8 Gy in 
1 fraction (800 cGy), 20 Gy in 5 fractions (2000 cGy), 30 Gy in 10 
fractions (3000 cGy), and 37.5 Gy in 15 fractions (3750 cGy). 8 Gy 
vs 20 Gy, P = .776; 8 Gy vs 37.5 Gy, P = .409; 20 Gy vs 37.5 Gy, 
P = .278; 30 Gy vs 8 Gy and 20 Gy, P < .0001; 30 Gy vs 37.5 Gy, 
P = .513
4250 |   FISCHER- VALUCK Et AL.
 12. Briganti A, Passoni N, Ferrari M, et al. When to perform bone 
scan in patients with newly diagnosed prostate cancer: external 
validation of the currently available guidelines and proposal of a 
novel risk stratification tool. Eur Urol. 2010;57:551‐558.
 13. Carlin BI, Andriole GL. The natural history, skeletal complica-
tions, and management of bone metastases in patients with pros-
tate carcinoma. Cancer. 2000;88(12 Suppl):2989‐2994.
 14. Rigaud J, Tiguert R, Le Normand L, et al. Prognostic value of bone 
scan in patients with metastatic prostate cancer treated initially 
with androgen deprivation therapy. J Urol. 2002;168:1423‐1426.
 15. Groot MT, Boeken Kruger CG, Pelger RC, Uyl-de Groot CA. 
Costs of prostate cancer, metastatic to the bone, in the Netherlands. 
Eur Urol. 2003;43:226‐232.
 16. Wu JS, Wong R, Johnston M, Bezjak A, Whelan T, Cancer Care 
Ontario Practice Guidelines Initiative Supportive Care Group. 
Meta- analysis of dose- fractionation radiotherapy trials for the 
palliation of painful bone metastases. Int J Radiat Oncol Biol 
Phys. 2003;55:594‐605.
 17. Chow E, Harris K, Fan G, Tsao M, Sze WM. Palliative radiother-
apy trials for bone metastases: a systematic review. J Clin Oncol. 
2007;25:1423‐1436.
 18. Roos DE, Turner SL, O’Brien PC, et al. Randomized trial of 8 Gy 
in 1 versus 20 Gy in 5 fractions of radiotherapy for neuropathic 
pain due to bone metastases (Trans- Tasman Radiation Oncology 
Group, TROG 96.05). Radiother Oncol. 2005;75:54‐63.
 19. Rutter CE, Yu JB, Wilson LD, Park HS. Assessment of national 
practice for palliative radiation therapy for bone metastases sug-
gests marked underutilization of single- fraction regimens in the 
United States. Int J Radiat Oncol Biol Phys. 2015;91:548‐555.
 20. Earle CC, Park ER, Lai B, Weeks JC, Ayanian JZ, Block S. 
Identifying potential indicators of the quality of end- of- life cancer 
care from administrative data. J Clin Oncol. 2003;21:1133‐1138.
 21. Earle CC, Landrum MB, Souza JM, Neville BA, Weeks JC, 
Ayanian JZ. Aggressiveness of cancer care near the end of life: is 
it a quality- of- care issue? J Clin Oncol. 2008;26:3860‐3866.
 22. Maranzano E, Trippa F, Casale M, et al. 8 Gy single- dose radio-
therapy is effective in metastatic spinal cord compression: results 
of a phase III randomized multicentre Italian trial. Radiother 
Oncol. 2009;93:174‐179.
 23. Zietman AL. The Red Journal’s most downloaded articles of 
2012. Int J Radiat Oncol Biol Phys. 2013;86:218‐221.
 24. Raman S, Chow R, Hoskin P, Chow E. How should radiation 
oncologists interpret the ASTRO evidence- based guideline and 
ASTRO Choosing Wisely campaign for the treatment of uncom-
plicated bone metastases? Pract Radiat Oncol. 2017;7:13‐15.
 25. Mitera G, Earle C, Latosinsky S, et al. Choosing Wisely Canada 
cancer list: ten low- value or harmful practices that should be 
avoided in cancer care. J Oncol Pract. 2015;11:e296‐e303.
 26. Fischberg D, Bull J, Casarett D, et al. Five things physicians and 
patients should question in hospice and palliative medicine. J 
Pain Symptom Manage. 2013;45:595‐605.
 27. van den Hout WB, van der Linden YM, Steenland E, et al. Single- 
versus multiple- fraction radiotherapy in patients with painful 
bone metastases: cost- utility analysis based on a randomized trial. 
J Natl Cancer Inst. 2003;95:222‐229.
 28. Konski A, James J, Hartsell W, et al. Economic analysis of radi-
ation therapy oncology group 97- 14: multiple versus single frac-
tion radiation treatment of patients with bone metastases. Am J 
Clin Oncol. 2009;32:423‐428.
 29. Collinson L, Kvizhinadze G, Nair N, McLeod M, Blakely 
T. Economic evaluation of single- fraction versus multiple- 
fraction palliative radiotherapy for painful bone metastases in 
breast, lung and prostate cancer. J Med Imaging Radiat Oncol. 
2016;60:650‐660.
 30. Bekelman JE, Epstein AJ, Emanuel EJ. Single- vs multiple- 
fraction radiotherapy for bone metastases from prostate cancer. 
JAMA. 2013;310:1501‐1502.
 31. Olson RA, Tiwana MS, Barnes M, et  al. Use of single- versus 
multiple- fraction palliative radiation therapy for bone metastases: 
population- based analysis of 16,898 courses in a Canadian prov-
ince. Int J Radiat Oncol Biol Phys. 2014;89:1092‐1099.
 32. Olson RA, Tiwana M, Barnes M, et al. Impact of using audit data 
to improve the evidence- based use of single- fraction radiation 
therapy for bone metastases in British Columbia. Int J Radiat 
Oncol Biol Phys. 2016;94:40‐47.
How to cite this article: Fischer-Valuck BW, Baumann 
BC, Apicelli A, et al. Palliative radiation therapy (RT) 
for prostate cancer patients with bone metastases at 
diagnosis: A hospital- based analysis of patterns of care, 
RT fractionation scheme, and overall survival. Cancer 
Med. 2018;7:4240–4250. https://doi.org/10.1002/
cam4.1655
